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Abstract: 
Introduction: Primary endocrine therapy (PET) is used variably in the UK as an alternative to surgery 
for older women with operable breast cancer. Guidelines state that only patients with significant 
comorbidity or reduced life expectancy should be treated this way and age should not be a factor. 
Methods: A Discrete Choice Experiment (DCE) was used to determine the impact of key variables 
(patient age, comorbidity, cognition, functional status, cancer stage, cancer biology) on healthcare 
professionals (HCP) treatment preferences for operable breast cancer among older women. 
Multinomial logistic regression was used to identify associations. 
Results: 40% (258/641) of questionnaires were returned. Five variables (age, co-morbidity, 
cognition, functional status and cancer size) independently demonstrated a significant association 
with treatment preference (p<0.05). Functional status was omitted from the multivariable model 
due to collinearity, with all other variables correlating with a preference for operative treatment 
over no preference (p<0.05). Only co-morbidity, cognition and cancer size correlated with a 
preference for PET over no preference (p<0.05).  
Conclusion: The majority of respondents selected treatment in accordance with current guidelines, 
however in some scenarios, opinion was divided, and age did appear to be an independent factor 
that HCPs considered when making a treatment decision in this population.  
 
Key words: Breast cancer, primary endocrine therapy, surgery, discrete choice experiment, older. 
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Introduction. 
A third of new breast cancer diagnoses occur in women age over 70 years in the UK [1]. This 
proportion will continue to increase as the population ages [2]. Older patients have higher rates of 
comorbidity and frailty so that the risk of death from breast cancer is relatively reduced, with only 
23% deaths due to breast cancer for patients diagnosed in their mid-80s compared to 73% for 
patients diagnosed in their 50s [3]. Older patients with operable breast cancer may be offered 
alternative treatment modalities, such as primary endocrine therapy (PET) [4, 5], wherein oestrogen 
receptor (ER) positive disease may be treated with endocrine therapy alone.  
A Cochrane review comparing PET with surgery based on trials conducted over 20 years ago 
demonstrated no difference in overall survival between the two treatments, however there were 
superior rates of local disease control in the surgical group [6]. None of these studies assessed the 
impact of comorbidity or frailty, and a recent review of case series indicated that older frailer 
women tend to be treated with PET and have inferior overall survival rates as would be expected 
due to higher other-cause mortality [7]. 
National audits have demonstrated significant variation in the use of PET to treat older women 
across the UK [8] which is not fully explained by  case mix variation (stage, deprivation, etc.) [9]. 
Healthcare professional (HCP) preference may be a source of some of this variation [10] and this 
factor may exert a potent influence on patient choice [11]. A recent study demonstrated 
considerable variation in HCP opinion regarding the factors important in breast cancer treatment 
decision making in this population [12]. 
This aim of this study was to use Discrete Choice Experiment (DCE) methodology to determine the 
impact of key variables on HCP treatment preferences for the management of operable breast 
cancer in older women. DCE is a rigorous survey methodology capable of eliciting individuals 
preferences in controlled experimental conditions, through responses to hypothetical scenarios [13], 
based on the assumption that the patients in the scenarios can be described by certain 
characteristics and that an individuals treatment preference depends upon these characteristics 
[14]. 
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Materials and Methods:  
The DCE method was chosen to establish HCP preferences in controlled experimental conditions 
using hypothetical scenarios. Key variables were identified and selected using the relevant literature 
and subdivided into levels of clinical severity based on clinical expert peer review. Table 1 shows the 
variables and levels. Twenty-five scenarios were randomly generated using IBM SPSS version 21 
Orthoplan software out of 3,072 potential scenarios. For each scenario the participants were asked 
to indicate a preference for PET or operative treatment for a hypothetical older woman with 
operable breast cancer. In order to optimise reality in clinical practice, an opt out option was 
included, whereby respondents could indicate no preference for either treatment choice [15]. It was 
felt that this would more closely reflect HCP decision-making and therefore enhance response rates 
compared to the more conventional pair-wise choice design [16]. 
We calculated that in order to estimate the preference for a given scenario with a reasonable degree 
of precision of say +/-6% (assuming a 50% preference) i.e. 95% confidence interval 44% to 56% 
would require 250 responders to the survey. 
To be effective, scenarios must be plausible and so the questionnaire was piloted with a selection of 
experienced HCPs who identified eight of the 25 scenarios as being unrealistic. These were excluded 
from the final instrument. An experienced geriatrician, together with a panel of clinical breast 
specialists, examined the plausible scenarios and estimated the predicted life-expectancy for each 
hypothetical patient based on their age, levels of co-morbidity, cognition and functional status, 
which were categorised as <2 years, 2-5 years and >5 years.  Life expectancy of less than 2 years 
would be an indicator that primary endocrine therapy would be a good choice with minimal 
morbidity in a woman in whom the breast cancer is unlikely to contribute to the cause of death.  
Conversely as literature suggests that the median duration of disease control with PET is 2 years, use 
of this treatment option for a woman with an estimated life expectancy of more than 5 years would 
be unlikely to result in long term disease control without change of management.   The predicted life 
expectancy of each patient scenario was NOT shown to the questionnaire respondents as this 
information would not be routinely available in normal clinical practice. Figure 1 illustrates a 
scenario example. The final 17 discrete choice scenarios were incorporated into a postal 
questionnaire that was mailed to all clinician and nurse members of the UK Association of Breast 
Surgery (ABS). An electronic reminder was sent via email to all members after four months. 
University of Sheffield Research Ethics Committee approvals were obtained (SMBRER243). 
Since the outcome for each scenario had three nominal levels (for operation, for PET, prefer 
both equally) multinomial logistic regression was used to identify associations between the 
5 
 
outcome variable (treatment preference) and the various clinical characteristics given in the 
scenarios (patient age, comorbidity, cognition, functional status, cancer stage, cancer biology). A 
multinomial logistic model was fitted in Stata (Statacorp version 13) with prefers either as the 
reference category. Robust standard errors for the regression coefficient estimates were used to 
calculate confidence intervals and P-values to allow for the clustered nature of the data since 
outcomes were clustered by participant to take into account the lack of response independence (as 
each participant answered 17 scenarios). 
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Results:  
Questionnaires were sent out in February 2014.  Of the 641 questionnaires distributed, 258 were 
returned (40.2% response rate): 45.6% male, 53.2% female, 75.4% breast surgeons, 21.8% clinical 
nurse specialist, 2.0% others (oncologists, breast physician, plastic surgeons). The median age of 
respondents was 50 years (range 28-69 years). Of these, 4 did not complete the DCE section as they 
were oncologists or plastic surgeons.  
The 258 responders answered 4,281 of the 4,386 scenarios (258 x 17). In 53% (2,279/4,281) of the 
scenarios, responders preferred operative treatment, 25% (1063/4281) PET, and 22% (939/4281) 
preferred both equally. Seventy-eight percent (199/254) of responders demonstrated a preference 
for operative treatment in the majority of the scenarios they rated, 9% (22/254) a preference for 
PET, and 13% (33/254) an equal preference for surgery and PET. Table 2 summarises the results by 
scenario.  
A response of no preference was treated as the reference treatment option compared with 
preference for operation and prefers PET using univariate and multivariate analysis. Five of the 
six variables (age, co-morbidity, cognition, functional status and cancer size) independently 
demonstrated a statistically signification association with treatment preference on univariate 
analysis (p<0.05). The variable cancer biology (receptor status) was associated with a treatment 
preference for operation over no preference (p<0.001) but not for PET (p=0.966) i.e. had a weaker 
effect on preference than the other variables. However, it should be noted that all options were ER 
positive so this is not surprising. 
On multivariable analysis, functional status had to be omitted from the model due to collinearity; 
this is most likely due to the close association between this variable and the variables co-morbidity 
and cognition (e.g. a patient with moderate or severe co-morbidity and or cognitive dysfunction 
must inevitably also have moderate or severe functional dependence) and so the model could not 
determine whether an observed effect was due to functional status or co-morbidity/cognition. Table 
3 summarises the multivariable analysis results. Overall, all five variables in the model were 
associated with a preference for operative treatment over no preference. However, only co-
morbidity, cognition and cancer size were associated with a preference for PET over no preference. 
The goodness of fit of the multivariable model was assessed by the pseudo R2 value. In this case, the 
pseudo R2 value for the model is 0.31, suggesting this model including these five covariates is better 
than a model including no covariates by 31%, but is worse than the theoretical perfect fitting model 
(which would have a pseudo R2 value of 1.0). 
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The majority of respondents selected treatment in accordance with the patients predicted life 
expectancy for most scenarios, which is consistent with current guidelines [17]. However in some 
scenarios, opinion was divided, for example scenarios 3, 4 and 7. 
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Discussion:  
This DCE has confirmed the influence of several predictable factors on HCP decision making in the 
management of older patients with operable breast cancer. To our knowledge, this is the first 
application of a DCE in this setting. The results must be interpreted with a note of caution due to the 
overall response rate of 40% which limits their generalizability, although we can still estimate the 
preference for different scenarios with a reasonable degree of precision. This rate is lower than the 
average response rate for postal surveys of doctors quoted in the literature [18], however is 
comparable with studies conducted on a similar population [19]. Additionally, a limitation of this 
study, which can be said of any survey methodology, is related to external validity and whether the 
participants would behave the same way in a real clinical context as they do in the hypothetical 
scenario.  
Recent national guidelines state that patients with operable breast cancer should be treated with 
surgery, and not PET, irrespective of age unless this is precluded by comorbidities [20]; whilst the 
International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists 
(EUSOMA) recommend that PET should only be offered to patients with short estimated life 
expectancy (<2-3 years), who are considered unfit for surgery or who refuse surgery [17]. 
However, life expectancy is impossible to accurately assess with any certainty, and although 
considered important by HCPs in determining treatment for older patients with operable breast 
cancer [12], a recent study has shown that surgeons are poor at gauging life-expectancy of older 
patients, with a tendency to under-estimate it [21]. Additionally, these current guidelines do not 
specify which comorbidities may preclude surgery or what constitutes being unfit and as such it is 
left to the treating HCP to determine which patients are considered unsuitable for surgery based on 
the clinical information available.  
Increasing rates of comorbidity with age have been shown to potentially reduce the survival 
advantage of more aggressive breast cancer therapies [22] and higher levels of comorbidity have 
been shown to be associated with non-surgical treatment [23]. These results confirm that the degree 
of comorbidity is a significant factor for HCPs in determining treatment options for older patients 
with operable breast cancer thus arguably reflecting why comorbidities are often stated as a reason 
for treating patients with PET [21, 24] 
Age also appears to be an independent factor that HCPs consider to be important when making a 
treatment decision in this population. This being consistent with several studies that have identified 
a reduction in surgery rates with increasing age for older patients with operable breast cancer [4, 25, 
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26]. This is most likely due to chronological age often being used by HCPs as a surrogate marker for 
other factors that are more difficult to quantify, such as life expectancy and frailty [27].  
Additionally, dementia, predominantly affecting the elderly, represents a significant problem, 
though there are currently no guidelines for the treatment of operable breast cancer in this group of 
patients. Furthermore a recent study demonstrated a lack of consensus among HCPs regarding the 
optimal way to treat this group [12]. Older patients with dementia are less likely to receive standard 
cancer therapies [28] and this is often stated as an explanation for selecting PET over surgery [5, 29]. 
These results confirm that HCPs are less likely to prefer surgery and more likely to opt for PET for 
patients with moderate and severe cognitive impairment. 
Tumour factors were also shown to have an independent influence over the HCPs treatment 
preference. Larger tumours were associated with lower rates of preference for surgery. This may 
reflect the fact that larger tumours are more likely to require mastectomy rather than breast 
conservation surgery and HCPs may wish to avoid more major surgery, although exact tumour size 
was not specified in the scenarios. Interestingly, preference for surgery significantly increased with 
increasing ER status but preference for PET did not. This is contrary to what might be expected as 
response rates for PET are generally higher for patients with greater ER positivity [30]. Additionally, 
preference for surgery increased for HER2 negative tumours but there was no difference in 
preference for PET, despite the fact that HER2 positive cancers are known to be generally less likely 
to respond to endocrine therapy [31]. However, the scenarios only contained limited information on 
the receptor status and combined ER and HER2 status, without specifying any values, making the 
results slightly more difficult to interpret. Additionally, the majority of HCPs surveyed were breast 
surgeons (75.4%) and whilst this type of decision-making is commonly undertaken by the treating 
breast surgeon in the UK, a different HCP population, for example oncologists, may have yielded 
different results. 
In 2008 the UKs Department of Health established the National Cancer Equality Initiative (NCEI) 
aiming at lowering the inequality in cancer outcomes for all, including those of older patients [32]. 
The treatment of older breast cancer patients across the UK is variable, with rates of PET ranging 
from 10-40% [8]. Healthcare professional recommendation has been shown to be the most 
influential factor affecting older womens breast cancer treatment decisions [11], and several studies 
have suggested that variation in treatment may reflect the differing opinions of HCPs so influencing 
communication of treatment options [10]. This study supports these findings and emphasises the 
need for evidence-based guidelines on decision-making in this age group.  
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In conclusion, the majority of HCPs within this study selected treatment in accordance with current 
guidelines relating to the presence of significant comorbidity. However, in some scenarios, opinion 
was divided and age did appear to be an independent factor that HCPs considered when making a 
treatment decision in this population. This study demonstrates that HCP preferences for managing 
older breast cancer patients are not uniform, which may contribute to the treatment variation seen 
in this population. 
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Figure 1: Scenario example 
PATIENT AGE (YEARS) 85+ 
CO-MORBIDITY 
TUMOUR STAGE 
NONE 
SMALL TUMOUR, NODE POSITIVE 
BREAST CANCER BIOLOGY ER++ / HER2- 
FUNCTIONAL STATUS MODERATE DEPENDENCE  
COGNITIVE FUNCTION SEVERE IMPAIRMENT  
For Operation                    [   ]  
Prefer both equally            [   ]           
For PET                                 [   ] 
 
 
Please indicate your preferred choice of recommendation for treatment (i.e. in favour 
of operative treatment or primary endocrine therapy (PET), by placing a tick (9) in the 
relevant box below the scenario description.  Please assume that each hypothetical 
patient has asked you to advise them on what treatment option they should choose. 
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Table 1: Discrete choice variables and levels. 
Variable Levels 
Patient age 70-74 75-79 80-84 85+ 
Co-morbidity None Mild Moderate Severe 
Cognition Normal Mild impairment Moderate 
Impairment 
Severe Impairment 
Functional 
status* 
Independent Mild dependence Moderate 
dependence 
Severe 
dependence 
Cancer size Small tumour, 
node negative 
Small tumour, 
node positive 
Large tumour, 
node negative 
Large tumour, 
node positive 
Cancer 
biology 
ER positive, HER2 
positive 
ER positive, HER2 
negative 
ER strongly positive, HER2 
negative 
*denotes not included in final model 
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Table 2: Results by scenario (maximum N=254 responders) 
Scenario Patient 
Age 
Co-morbidity Cognition Functional status Cancer size Cancer biology Predicted life 
expectancy 
Preference 
for PET 
Prefer both 
equally 
Preference for 
Surgery 
1 85+ Severe Normal Severe dependence Small, node negative ER+, HER2+ <2 years 218 
(86.2%) 
20 
(7.9%) 
15 
(5.9%) 
2 85+ None Severe impairment Moderate dependence Small, node positive ER++, HER2- <2 years 155 
(61.3%) 
66 
(26.1%) 
32 
(12.6%) 
3 70-74 Severe Normal Moderate dependence Large, node negative ER+, HER2+ <2 years 111 
(43.9%) 
78 
(30.8%) 
64 
(25.3%) 
4 80-84 None Moderate impairment Severe dependence Small, node negative ER+, HER2+ <2 years 108 
(43.0%) 
80 
(31.9%) 
63 
(25.1%) 
5 70-74 None Severe impairment Severe dependence Large, node negative ER+, HER2- <2 years 156 
(62.2%) 
65 
(25.9%) 
30 
(12.0%) 
6 85+ Moderate Moderate impairment Mild dependence Large, node negative ER++, HER2- 2-5 years 115 
(45.6%) 
104 
(41.3%) 
33 
(13.1%) 
7 75-79 Moderate Normal Severe dependence Large, node positive ER++, HER2- 2-5 years 100 
(40.0%) 
95 
(38.0%) 
55 
(22.0%) 
8 80-84 Moderate Mild impairment Moderate dependence Small, node negative ER+, HER2- 2-5 years 39 
(15.6%) 
113 
(45.2%) 
98 
(39.2%) 
9 85+ None Mild impairment Independent Large, node positive ER+, HER2+ 2-5 years 20 
(7.9%) 
60 
(23.8%) 
172 
(68.3%) 
10 70-74 Mild Moderate impairment Moderate dependence Large, node positive ER+, HER2- 2-5 years 16 
(6.3%) 
54 
(21.4%) 
182  
(72.2%) 
11 70-74 None Normal Mild dependence Large, node positive ER+, HER2- >5 years 6 
(2.4%) 
14 
(5.6%) 
231 
(92.0%) 
12 85+ Mild Normal Independent Small, node negative ER+, HER2- >5 years 3 
(1.2%) 
52 
(20.6%) 
198 
(78.3%) 
13 80-84 None Normal Mild dependence Small, node positive ER+, HER2- >5 years 2 
(1.2%) 
39 
(15.5%) 
210 
(83.7%) 
14 70-74 Moderate Normal Independent Small, node positive ER+, HER2+ >5 years 2 
(0.8%) 
22 
(8.8%) 
227 
(90.4%) 
15 70-74 None Normal Independent Small, node negative ER++, HER2- >5 years 0 
(0.0%) 
2 
(0.8%) 
251 
(99.2%) 
16 75-79 None Mild Impairment Independent Large, node negative ER+, HER2- >5 years 5 
(2.0%) 
25 
(9.9%) 
223 
(88.1%) 
17 80-84 Mild Normal Independent Large, node negative ER++, HER2- >5 years 7 
(2.8%) 
50 
(19.8%) 
195 
(77.4%) 
*highlighted area demonstrate respondents overall preference for surgery, PET or both equally by scenario 
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Table 3: Influence of DCE variable over treatment choice (N=248 responders). 
Variable  Surgery vs equal preference PET vs equal preference 
 Levels RRR  95% C.I. P-value RRR 95% C.I. P-value 
Age 70-74 Ref - - Ref - - 
75-79 0.12 0.06-0.22 <0.001 2.05 0.88-4.77 0.096  
80-84 0.06 0.03-0.11 <0.001 2.48 0.98-6.25 0.055  
85+ 0.11 0.06-0.19 <0.001 1.84 0.78-4.34 0.166  
  
Co-morbidity None Ref - - Ref - - 
Mild 0.67 0.46-0.99 0.043 0.24 0.12-0.46 <0.001 
Moderate 0.11 0.07-0.17 <0.001 0.95 0.33-2.74 0.923 
Severe 0.05 0.03-0.09 <0.001 20.70 8.44-50.73 <0.001 
  
Cognition Normal Ref - - Ref - - 
Mild impairment 2.46 1.63-3.72 <0.001 0.74 0.35-1.55 0.424  
Moderate impairment 0.32 0.24-0.42 <0.001 3.67 2.07-6.48 <0.001 
Severe impairment 0.01 0.01-0.03 <0.001 21.45 7.01-65.57 <0.001 
  
Cancer size Small, node- Ref - - Ref - - 
Small, node+ 1.77 1.22-2.56 0.003 0.18 0.09-0.40 <0.001 
Large, node- 0.47 0.30-0.76 0.002 0.53 0.29-0.97 0.039 
Large, node+ 0.25 0.15-0.43 <0.001 1.68 0.81-3.44 0.161 
  
Cancer biology ER+,HER2+ Ref - - Ref - - 
ER+, HER2- 1.44 1.11-1.86 0.006 1.41 0.76-2.60 0.273 
ER++, HER2- 4.51 2.26-8.98 <0.001 2.27 0.53-9.72 0.269 
 
RRR = Relative Risk Ratio 
 
 
 
Table 1: Discrete choice variables and levels. 
Variable Levels 
Patient age 70-74 75-79 80-84 85+ 
Co-morbidity None Mild Moderate Severe 
Cognition Normal Mild impairment Moderate 
Impairment 
Severe Impairment 
Functional 
status* 
Independent Mild dependence Moderate 
dependence 
Severe 
dependence 
Cancer size Small tumour, 
node negative 
Small tumour, 
node positive 
Large tumour, 
node negative 
Large tumour, 
node positive 
Cancer 
biology 
ER positive, HER2 
positive 
ER positive, HER2 
negative 
ER strongly positive, HER2 
negative 
*denotes not included in final model 
 
Table 2: Results by scenario (maximum N=254 responders) 
Scenario Patient 
Age 
Co-morbidity Cognition Functional status Cancer size Cancer biology Predicted life 
expectancy 
Preference 
for PET 
Prefer both 
equally 
Preference for 
Surgery 
1 85+ Severe Normal Severe dependence Small, node negative ER+, HER2+ <2 years 218 
(86.2%) 
20 
(7.9%) 
15 
(5.9%) 
2 85+ None Severe impairment Moderate dependence Small, node positive ER++, HER2- <2 years 155 
(61.3%) 
66 
(26.1%) 
32 
(12.6%) 
3 70-74 Severe Normal Moderate dependence Large, node negative ER+, HER2+ <2 years 111 
(43.9%) 
78 
(30.8%) 
64 
(25.3%) 
4 80-84 None Moderate impairment Severe dependence Small, node negative ER+, HER2+ <2 years 108 
(43.0%) 
80 
(31.9%) 
63 
(25.1%) 
5 70-74 None Severe impairment Severe dependence Large, node negative ER+, HER2- <2 years 156 
(62.2%) 
65 
(25.9%) 
30 
(12.0%) 
6 85+ Moderate Moderate impairment Mild dependence Large, node negative ER++, HER2- 2-5 years 115 
(45.6%) 
104 
(41.3%) 
33 
(13.1%) 
7 75-79 Moderate Normal Severe dependence Large, node positive ER++, HER2- 2-5 years 100 
(40.0%) 
95 
(38.0%) 
55 
(22.0%) 
8 80-84 Moderate Mild impairment Moderate dependence Small, node negative ER+, HER2- 2-5 years 39 
(15.6%) 
113 
(45.2%) 
98 
(39.2%) 
9 85+ None Mild impairment Independent Large, node positive ER+, HER2+ 2-5 years 20 
(7.9%) 
60 
(23.8%) 
172 
(68.3%) 
10 70-74 Mild Moderate impairment Moderate dependence Large, node positive ER+, HER2- 2-5 years 16 
(6.3%) 
54 
(21.4%) 
182  
(72.2%) 
11 70-74 None Normal Mild dependence Large, node positive ER+, HER2- >5 years 6 
(2.4%) 
14 
(5.6%) 
231 
(92.0%) 
12 85+ Mild Normal Independent Small, node negative ER+, HER2- >5 years 3 
(1.2%) 
52 
(20.6%) 
198 
(78.3%) 
13 80-84 None Normal Mild dependence Small, node positive ER+, HER2- >5 years 2 
(1.2%) 
39 
(15.5%) 
210 
(83.7%) 
14 70-74 Moderate Normal Independent Small, node positive ER+, HER2+ >5 years 2 
(0.8%) 
22 
(8.8%) 
227 
(90.4%) 
15 70-74 None Normal Independent Small, node negative ER++, HER2- >5 years 0 
(0.0%) 
2 
(0.8%) 
251 
(99.2%) 
16 75-79 None Mild Impairment Independent Large, node negative ER+, HER2- >5 years 5 
(2.0%) 
25 
(9.9%) 
223 
(88.1%) 
17 80-84 Mild Normal Independent Large, node negative ER++, HER2- >5 years 7 
(2.8%) 
50 
(19.8%) 
195 
(77.4%) 
*highlighted area demonstrate respondents overall preference for surgery, PET or both equally by scenario 
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Mild 0.67 0.46-0.99 0.043 0.24 0.12-0.46 <0.001 
Moderate 0.11 0.07-0.17 <0.001 0.95 0.33-2.74 0.923 
Severe 0.05 0.03-0.09 <0.001 20.70 8.44-50.73 <0.001 
  
Cognition Normal Ref - - Ref - - 
Mild impairment 2.46 1.63-3.72 <0.001 0.74 0.35-1.55 0.424  
Moderate impairment 0.32 0.24-0.42 <0.001 3.67 2.07-6.48 <0.001 
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Small, node+ 1.77 1.22-2.56 0.003 0.18 0.09-0.40 <0.001 
Large, node- 0.47 0.30-0.76 0.002 0.53 0.29-0.97 0.039 
Large, node+ 0.25 0.15-0.43 <0.001 1.68 0.81-3.44 0.161 
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Figure 1: Scenario example 
PATIENT AGE (YEARS) 85+ 
CO-MORBIDITY 
TUMOUR STAGE 
NONE 
SMALL TUMOUR, NODE POSITIVE 
BREAST CANCER BIOLOGY ER++ / HER2- 
FUNCTIONAL STATUS MODERATE DEPENDENCE  
COGNITIVE FUNCTION SEVERE IMPAIRMENT  
For Operation                    [   ]  
Prefer both equally            [   ]           
For PET                                 [   ] 
 
 
Please indicate your preferred choice of recommendation for treatment (i.e. in favour 
of operative treatment or primary endocrine therapy (PET), by placing a tick (9) in the 
relevant box below the scenario description.  Please assume that each hypothetical 
patient has asked you to advise them on what treatment option they should choose. 
 
